Vadastuximab is a novel antibody-drug compound representing a important advancement in the management of acute myeloid leukemia (AML). This innovative therapy selectively targets CD33, a marker frequently https://bookmark-template.com/story28569723/vadastuximab-a-deep-dive-into-cd33-targeted-therapy